Palbociclib (PD-0332991) HCl

Name: Palbociclib (PD-0332991) HCl
Brand: Selleck Chemicals
SKU: S1116
Rating: 5 (177 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1116

177 publications

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Selleck's Palbociclib (PD-0332991) HCl has been cited by 177 publications

Cell, 2020, 16;181(2):424-441e21

PubMed: 32234521 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):340-353

PubMed: 32109375 ( click the link to review the publication )

Cell, 2019, 176(5):1083-1097

PubMed: 30739799 ( click the link to review the publication )

Nat Med, 2019, 25(2):292-300

PubMed: 30664779 ( click the link to review the publication )

Cancer Discov, 2019, 10.1158/2159-8290.CD-18-0830

PubMed: 31594766 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2018, 553(7686):91-95

PubMed: 29160310 ( click the link to review the publication )

Cell, 2018, 174(5):1127-1142

PubMed: 30078706 ( click the link to review the publication )

Cancer Discov, 2017, 7(10):1168-1183

PubMed: 28801307 ( click the link to review the publication )

Nat Immunol, 2017, 18(3):293-302

PubMed: 28092373 ( click the link to review the publication )

Nat Immunol, 2017, 18(3):293-302

PubMed: 28092373 ( click the link to review the publication )

Nat Commun, 2020, 11(1):71

PubMed: 31900415 ( click the link to review the publication )

Nat Commun, 2020, 11(1):385

PubMed: 31959756 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2706

PubMed: 32086342 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

J Cell Biol, 2020, 1;219(6)

PubMed: 32236513 ( click the link to review the publication )

J Cell Biol, 2020, 2;219(3)

PubMed: 32211891 ( click the link to review the publication )

Elife, 2020, 7;9:e44571

PubMed: 32255427 ( click the link to review the publication )

Cancers (Basel), 2020, 6;12(4)

PubMed: 32268485 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32197329 ( click the link to review the publication )

Cells, 2020, 26;9(4)

PubMed: 32225025 ( click the link to review the publication )

Cancer Discov, 2020, 13;CD-19-1390

PubMed: 32404308 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32046095 ( click the link to review the publication )
Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Breast Cancer, 2020, 10.1007/s12282-020-01090-3

PubMed: 32297248 ( click the link to review the publication )

Nat Struct Mol Biol, 2020, 27(1):92-104

PubMed: 31925410 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Gut, 2019, 68(2):207-217

PubMed: 29703791 ( click the link to review the publication )

Nat Microbiol, 2019, 4(12):2260-2272

PubMed: 31548682 ( click the link to review the publication )

Mol Cell, 2019, 76(4):562-573

PubMed: 31543423 ( click the link to review the publication )

Mol Cell, 2019, 73(1):22-35.e6

PubMed: 30527665 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1373

PubMed: 30914635 ( click the link to review the publication )

Nat Commun, 2019, 10(1):557

PubMed: 30718506 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2769

PubMed: 30692100 ( click the link to review the publication )

PLoS Biol, 2019, 17(3):e3000178

PubMed: 30865623 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2466-2479

PubMed: 30940663 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(7):2290-2304

PubMed: 30538111 ( click the link to review the publication )

Cell Rep, 2019, 26(10):2667-2680

PubMed: 30840889 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.119.232603

PubMed: 31481582 ( click the link to review the publication )

Oncogene, 2019, 38(20):3886-3902

PubMed: 30692638 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)

PubMed: 31100952 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):271

PubMed: 30894510 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):376

PubMed: 31092814 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )
Cells, 2019, 8(10)

PubMed: 31590445 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(2):300-306

PubMed: 30595531 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):771-779

PubMed: 30837298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0162

PubMed: 31395685 ( click the link to review the publication )

Mol Oncol, 2019, 13(8):1778-1794

PubMed: 31180176 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(1):465-489

PubMed: 29721855 ( click the link to review the publication )

Oncogenesis, 2019, 8(7):38

PubMed: 31209198 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 163:133-141

PubMed: 30772267 ( click the link to review the publication )

J Transl Med, 2019, 17(1):245

PubMed: 31358010 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13405

PubMed: 31527634 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13696

PubMed: 31548560 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.29249

PubMed: 31264276 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1685289

PubMed: 31747859 ( click the link to review the publication )

Exp Cell Res, 2019, 10.1016/j.yexcr.2019.111782

PubMed: 31857114 ( click the link to review the publication )

Am J Transl Res, 2019, 11(6):3481-3489

PubMed: 31312360 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223555

PubMed: 31600301 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(4):967-973

PubMed: 31005255 ( click the link to review the publication )

Leuk Res, 2019, 78:3-11

PubMed: 30641417 ( click the link to review the publication )

Oncol Lett, 2019, 17(1):1153-1159

PubMed: 30655877 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 5:22

PubMed: 31372497 ( click the link to review the publication )
Nucleic Acids Res, 2019, 47(8):3921-3936

PubMed: 30805632 ( click the link to review the publication )

NPJ Precis Oncol, 2019, 03:18

PubMed: 31341951 ( click the link to review the publication )

Haematologica, 2019, 104(2):347-359

PubMed: 30262555 ( click the link to review the publication )

Oncotarget, 2019, 10(47):4907-4918

PubMed: 31448056 ( click the link to review the publication )

Eur J Med Chem, 2019, 165:115-132

PubMed: 30665142 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Gut, 2018, 10.1136/gutjnl-2017-314544

PubMed: 29884612 ( click the link to review the publication )

Mol Cell, 2018, 71(2):332-342

PubMed: 30017584 ( click the link to review the publication )

Mol Cell, 2018, 71(4):592-605

PubMed: 30057199 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(12):6188-6205

PubMed: 29873780 ( click the link to review the publication )

Autophagy, 2018, 14(4):637-653

PubMed: 29368982 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3994-4005

PubMed: 29716919 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-3094

PubMed: 30538112 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4360-4369

PubMed: 29844123 ( click the link to review the publication )

Cell Rep, 2018, 24(5):1105-1112.e5

PubMed: 30067968 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):112

PubMed: 30180865 ( click the link to review the publication )

Oncogene, 2018, 37(37):5066-5078

PubMed: 29789718 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):446

PubMed: 29670090 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):897-907

PubMed: 29483214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582

PubMed: 29452249 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )
Cell Signal, 2018, 44:1-9

PubMed: 29284139 ( click the link to review the publication )

J Orthop Res, 2018, 36(6):1581-1589

PubMed: 29194728 ( click the link to review the publication )

Cell Cycle, 2018, 17(11):1329-1344

PubMed: 30037299 ( click the link to review the publication )

Cell Cycle, 2018, 17(14):1784-1796

PubMed: 29995568 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):424-430

PubMed: 29477843 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 102(5):1569-1576

PubMed: 30056081 ( click the link to review the publication )

Oncotarget, 2018, 9(77):34567-34581

PubMed: 30349650 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2018, 21(5):375-382

PubMed: 29764587 ( click the link to review the publication )

Oncotarget, 2018, 9(102):37753-37765

PubMed: 30701029 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell, 2018, 10.1016/j.cell.2018.11.011

PubMed: 30580964 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1061-1070

PubMed: 28759028 ( click the link to review the publication )

Mol Cell, 2017, 68(6):1134-1146

PubMed: 29225033 ( click the link to review the publication )

Nat Commun, 2017, 8(1):607

PubMed: 28928360 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1193

PubMed: 29084956 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1995

PubMed: 29222471 ( click the link to review the publication )

Nat Commun, 2017, 8(1):241

PubMed: 28808226 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(10):1415-1433

PubMed: 28778953 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(22):6958-6968

PubMed: 28814434 ( click the link to review the publication )

Dev Cell, 2017, 43(4):449-462

PubMed: 29103955 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.26957

PubMed: 29889021 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):123

PubMed: 28629371 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(15):2427-2443

PubMed: 28444744 ( click the link to review the publication )
Mol Cancer Ther, 2017, 16(9):1942-1953

PubMed: 28566433 ( click the link to review the publication )

Cell Oncol (Dordr), 2017, 40(3):209-218

PubMed: 28243976 ( click the link to review the publication )

PLoS One, 2017, 12(8):e0181601

PubMed: 28806746 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(3):676-688

PubMed: 27338091 ( click the link to review the publication )

Protein Sci, 2017, 26(4):870-879

PubMed: 28168755 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Oncotarget, 2017, 8(56):95116-95134

PubMed: 29221116 ( click the link to review the publication )

Oncotarget, 2017, 8(34):55848-55862

PubMed: 28915557 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(4):489-501

PubMed: 28965767 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47239-47249

PubMed: 28525384 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:11581

PubMed: 27181366 ( click the link to review the publication )

Nat Commun, 2016, 7:12748

PubMed: 27599659 ( click the link to review the publication )

Nat Commun, 2016, 7:11302

PubMed: 27066737 ( click the link to review the publication )

Nat Commun, 2016, 7:11987

PubMed: 27329820 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(1):122-33

PubMed: 26728409 ( click the link to review the publication )

Cell Mol Life Sci, 2016, 73(4):883-900

PubMed: 26346493 ( click the link to review the publication )

PLoS Pathog, 2016, 12(8):e1005829

PubMed: 27541004 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2486-2497

PubMed: 27507850 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(10):3203-3219

PubMed: 27486199 ( click the link to review the publication )

J Cancer, 2016, 7(8):947-56

PubMed: 27313785 ( click the link to review the publication )

J Immunol, 2016, 197(7):2673-85

PubMed: 27566829 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2016, 310(7):C520-41

PubMed: 26718628 ( click the link to review the publication )
Oncotarget, 2016, 7(26):39595-39608

PubMed: 27167191 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51163-51173

PubMed: 27323399 ( click the link to review the publication )

Oncotarget, 2016, 7(43):69111-69123

PubMed: 27564114 ( click the link to review the publication )

J Natl Cancer Inst, 2015, 108(6):djv406

PubMed: 26719346 ( click the link to review the publication )

J Cell Biol, 2015, 210(7):1257-68

PubMed: 26416968 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:76

PubMed: 26225123 ( click the link to review the publication )

Anticancer Res, 2015, 35(12):6623-32

PubMed: 26637878 ( click the link to review the publication )

J Exp Med, 2015, 212(6):953-70

PubMed: 26008897 ( click the link to review the publication )

Data Brief, 2015, 5:429-33

PubMed: 26958605 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):662-74

PubMed: 24362465 ( click the link to review the publication )

AIDS, 2014, 28(15):2213-22

PubMed: 25036183 ( click the link to review the publication )

J Immunol, 2014, 193(4):1988-97

PubMed: 25015816 ( click the link to review the publication )

FEBS J, 2014, 281(18):4179-94

PubMed: 24823279 ( click the link to review the publication )

BMC Cancer, 2014, 14:32

PubMed: 24444383 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Universidade de Lisboa, 2014, Matias

PubMed: ( click the link to review the publication )

Cell Death Differ, 2013, 20(9):1241-9

PubMed: 23852369 ( click the link to review the publication )

Int J Cancer, 2013, 133(10):2341-50

PubMed: 23640782 ( click the link to review the publication )

PLoS Genet, 2013, 9(5):e1003546

PubMed: 23737759 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(12):2722-34

PubMed: 24107447 ( click the link to review the publication )

Pharmacogenomics J, 2013, 13(1):94-104

PubMed: 22083351 ( click the link to review the publication )
Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cell Cycle, 2013, 12(15):2384-94

PubMed: 23839043 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(17):4612-20

PubMed: 22761470 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2012, 26(2):236-46

PubMed: 23279822 ( click the link to review the publication )

Am J Cancer Res, 2012, 2(6):726-35

PubMed: 23226618 ( click the link to review the publication )

Cell Cycle, 2012, 11(19):3599-610

PubMed: 22935696 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51847

PubMed: 23300567 ( click the link to review the publication )

georgetown university, 2012, georgetown university

PubMed: ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(20):8414-9

PubMed: 21536883 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

Features

Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Targets

CDK4/CyclinD3 ^[1] (Cell-free assay)	CDK4/CyclinD1 ^[1] (Cell-free assay)	CDK6/CyclinD2 ^[1] (Cell-free assay)
9 nM	11 nM	15 nM

In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser⁷⁸⁰. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. ^[1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. ^[2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. ^[3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MOLM13	MX3LbY5ie2ViQYPzZZk>		MWWyOEBp		NVe3PGJlUW6qaXLpeIlwdiCxZjDDSGs1KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhWmJicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlAxOiEQvF2=	Mn3GNlQ3PDFzMEO=
COLO205	NEfaR4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEjaXHQ4OiCq		MoXCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO\|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB\|NjFOwG0>	MU[yOFY1OTFyMx?=
U937	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MX[3NkBp		NEfGXYNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt\|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMUSg{txO	M4\lcVI1PjRzMUCz
MOLM13	NXTjb4ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{DXUVczKGh?		M{OydGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIhiemKxcnnu[{BHVFR\|IFnUSEBufXSjboSgZZN{\XO\|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB7NjFOwG0>	M3LENFI1PjRzMUCz
MOLM13	M1;sVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M4n1b\|czKGh?		MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W\|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO	NYLWZppCOjR4NEGxNFM>
MDA-MB-435	Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGPT[YkzPCCq		NX7lWlNsUUN3ME2wMlE3KM7:TR?=	NX6zWZZSOTV6MEG4N\|E>
K562	NIXBem9EgXSxdH;4bYMhSXO\|YYm=		MoHYPVYhcA>?	NH:2enRFVVOR	NWrEWVJDUUN3ME2yJO69VQ>?	NX;kS5VMOjR2MUe1OlY>
DU145	MlPaR5l1d3SxeHnjJGF{e2G7		M{fGeVk3KGh?	MU\EUXNQ	MULJR\|UxRTdwNTFOwG0>	NWHyPJlyOjR2MUe1OlY>
MDA-MB-231	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTXSmliOSEQvF2=	MXWyOEBp	MoKxSG1UVw>?	NFq4TIZE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U>	NVnJbIpbOjR2MUe1OlY>
MCF7	NY\nU2oyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTBbnQyKM7:TR?=	MXWyOEBp	M3XQbGROW09?	NWr3V5FQS2WubDDjfYNt\SCjcoLld5Qh[XO\|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm	M{HZblI1PDF5NU[2
MCF7	MWrLbY5ie2ViQYPzZZk>	MVG1JO69VQ>?	MknSNlQhcA>?	MmXUSG1UVw>?	Ml3DTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?=	NGXUXZIzPDRzN{W2Oi=>
MDA-MB-231	MUHLbY5ie2ViQYPzZZk>	NUC5NHhxPSEQvF2=	NILjT5MzPCCq	M3rQWGROW09?	M13kOGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC=	M4\kTlI1PDF5NU[2
MDA-MB-231	MmDkSpVv[3Srb36gRZN{[Xl?	NVXUPVllOS1zMDFOwG0>	MojINlQhcA>?	NWPBSpR1TE2VTx?=	MYnkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m\|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V?	MX2yOFQyPzV4Nh?=
MCF7	M1TWTmZ2dmO2aX;uJGF{e2G7	NYPoU2R[OS1zMDFOwG0>	MWqyOEBp	NX3hcY0zTE2VTx?=	NVvPXnVj\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl	Mkn5NlQ1OTd3Nk[=
MDA-MB-231	NFr5OFJHfW6ldHnvckBCe3OjeR?=	NIrw[VkxNjVvMTFOwG0>	NVGxN3pNPDhiaB?=	M4TqTWROW09?	NUi3NZczcGG\|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V?	MXuyOFQyPzV4Nh?=
MCF7	NHXzNGJHfW6ldHnvckBCe3OjeR?=	Ml7VNE42NTFizszN	MkOwOFghcA>?	Mkn1SG1UVw>?	MWToZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=>	M4H3blI1PDF5NU[2
697	NVHSb3k{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTF2OD6zPEBvVQ>?	MoH1V2FPT0WU
P12-ICHIKAWA	NEfh[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjoWVBLUUN3ME25Ok4xPCCwTR?=	MmTLV2FPT0WU
NB69	NHLZTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;oZ2hqUUN3ME2xOlEvQCCwTR?=	M3faW3NCVkeHUh?=
EoL-1	NXj5eGlnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnFTWM2OD1zOEeuNlYhdk1?	M{fKW3NCVkeHUh?=
BHT-101	NWfIelRqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTF7OD6yOUBvVQ>?	M2D4cHNCVkeHUh?=
SK-NEP-1	MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rHZWlEPTB;MkKwMlAzKG6P	MYDTRW5ITVJ?
MHH-NB-11	Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nyNGlEPTB;MkKwMlE6KG6P	M2nPdnNCVkeHUh?=
AsPC-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1qwPGlEPTB;MkWyMlU{KG6P	NYnSTGZCW0GQR1XS
ES1	NWDVZo9JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTJ3Nj6yOUBvVQ>?	NUPp[mNpW0GQR1XS
LAMA-84	M4\KbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTJ3OD6xPUBvVQ>?	MYnTRW5ITVJ?
MOLT-16	NEKwXWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTJ3OD60PUBvVQ>?	MofJV2FPT0WU
ES7	NFSydHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3T5U2lEPTB;MkezMlA6KG6P	NVfaUXprW0GQR1XS
KY821	M3LnR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPyd5hMUUN3ME2zNVQvOSCwTR?=	MVzTRW5ITVJ?
RT-112	M2\SbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XZZ2lEPTB;M{KxMlA2KG6P	NFTsWJVUSU6JRWK=
HL-60	MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jWemlEPTB;M{SwMlY3KG6P	MXjTRW5ITVJ?
MOLT-4	M3S4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33CNmlEPTB;M{S1MlE{KG6P	MmnkV2FPT0WU
KARPAS-45	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTN5Nj6xOkBvVQ>?	MnXOV2FPT0WU
SK-N-AS	M4rPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTN6Nz64N{BvVQ>?	NGO2T5BUSU6JRWK=
CTB-1	NX3jNZFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGq1NnBKSzVyPUSwOU4xOiCwTR?=	MVnTRW5ITVJ?
NKM-1	NY\xd3NbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWXJTVd6UUN3ME20NVEvQDlibl2=	M3vFV3NCVkeHUh?=
HTC-C3	MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\BemlEPTB;NEOyMlk2KG6P	NU\DXlZzW0GQR1XS
BE-13	NVfpTYNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTR2ND6yO{BvVQ>?	Mn\UV2FPT0WU
KOSC-2	NG[4dGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfWZVFlUUN3ME20OlYvQSCwTR?=	NF;kRpFUSU6JRWK=
NB14	NGexfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzveVFMUUN3ME20PFMvPThibl2=	MlnBV2FPT0WU
CAL-27	NFLrOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGCwe5lKSzVyPUS5OE42QSCwTR?=	NVHnVYsxW0GQR1XS
H9	M3v2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\mdWlEPTB;NEm1MlQ{KG6P	NE[5W5pUSU6JRWK=
RS4-11	NFW2XVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Tt[GlEPTB;NUC0Mlc{KG6P	NFHDcWdUSU6JRWK=
PA-1	MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLNTWM2OD13MEmuPFYhdk1?	M3;0[3NCVkeHUh?=
MV-4-11	M2LGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTVzMz64OUBvVQ>?	MY\TRW5ITVJ?
OS-RC-2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTV{MT62NkBvVQ>?	NFPqNJNUSU6JRWK=
RPMI-8226	NEfBT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TMNGlEPTB;NUK2Mlg3KG6P	NEfMbZhUSU6JRWK=
HGC-27	MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnWwTWM2OD13NkSuPVkhdk1?	M1nR[nNCVkeHUh?=
CHP-212	M4DXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MknaTWM2OD13OUOuOVkhdk1?	NW\0OVRVW0GQR1XS
NB10	NFTM[HdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3f3S2lEPTB;NUm5MlE5KG6P	M3\DbnNCVkeHUh?=
HH	Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoHGTWM2OD13OUmuOFMhdk1?	MkP5V2FPT0WU
EW-16	NEDqcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmrTTWM2OD14MEOuOVIhdk1?	M4f0XHNCVkeHUh?=
ES8	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTZyNT6yNUBvVQ>?	MmTrV2FPT0WU
HAL-01	MnvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DYWGlEPTB;NkC1MlY4KG6P	M33vc3NCVkeHUh?=
A204	MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zETmlEPTB;NkOzMlkyKG6P	M3TCPXNCVkeHUh?=
MHH-PREB-1	NWjxNlRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4G4cGlEPTB;NkO2Mlk6KG6P	NVXwNJR6W0GQR1XS
EM-2	NFvrUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDXTWM2OD14NUCuOlQhdk1?	MX;TRW5ITVJ?
BV-173	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M321O2lEPTB;NkWyMlQ5KG6P	MWPTRW5ITVJ?
ONS-76	NHvGclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjuTWM2OD14N{euPFIhdk1?	MnfVV2FPT0WU
KM-H2	M{LTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTZ7NT61OEBvVQ>?	M{jqVnNCVkeHUh?=
D-263MG	M3zicmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\C[WlEPTB;N{G3MlEzKG6P	Ml7KV2FPT0WU
ES3	NX3Qc2Q1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\PfJZKSzVyPUeyPE46OyCwTR?=	M1fnS3NCVkeHUh?=
VA-ES-BJ	MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXLcpFKSzVyPUezNk4zPyCwTR?=	NFjJWXNUSU6JRWK=
NBsusSR	MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjrcGZYUUN3ME23OFIvQTlibl2=	M4LBdnNCVkeHUh?=
NCI-H520	Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHMTWM2OD15NE[uOVIhdk1?	M4TRPXNCVkeHUh?=
ES5	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTd3Mj64JI5O	Mn23V2FPT0WU
T-24	MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\iS4d4UUN3ME23O\|gvPzFibl2=	NVPIdYFyW0GQR1XS
SW962	NFnPfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLDc5dFUUN3ME24NFgvPjNibl2=	MkXoV2FPT0WU
EW-3	NHXXSWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPPTWM2OD16MEiuO\|Yhdk1?	MnO4V2FPT0WU
RXF393	M{nHdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDQTWM2OD16MUKuO\|khdk1?	MlnjV2FPT0WU
U251	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRThzMz64PEBvVQ>?	MoPPV2FPT0WU
CAMA-1	NYHFUFRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTh\|Mz65OEBvVQ>?	NGfaV2hUSU6JRWK=
JVM-3	NGDOdmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTh3MT63PEBvVQ>?	NEDpVm5USU6JRWK=
COLO-800	M{DSSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFH6W2dKSzVyPUi5O{44QCCwTR?=	NXL4Z2h3W0GQR1XS
OVCAR-5	NIfXSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTlyMD6xJI5O	MnHxV2FPT0WU
LB1047-RCC	NX6wT3lHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfzdolXUUN3ME25NlcvPTZibl2=	NGDvUIZUSU6JRWK=
SW954	NXm4dZRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTl{OT60NUBvVQ>?	MVXTRW5ITVJ?
J-RT3-T3-5	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HhdWlEPTB;OUO2MlA3KG6P	M4r5b3NCVkeHUh?=
Mewo	M3LxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fReWlEPTB;OUO2MlYhdk1?	M1jrVXNCVkeHUh?=
NCI-H1770	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDiZXJkUUN3ME25OFAvPTVibl2=	MXHTRW5ITVJ?
HO-1-N-1	NH[2WXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzZTWM2OD17NkKuPFEhdk1?	NVTXR21EW0GQR1XS
HSC-3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTl4Nj60PEBvVQ>?	MoLtV2FPT0WU
TYK-nu	M1jMUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTl7OD6yOUBvVQ>?	Mon3V2FPT0WU
KYSE-150	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrNOHZ5UUN3ME2xMlAxODd4IN88US=>	M3;TV3NCVkeHUh?=
SN12C	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLNUZRJUUN3ME2xMlAxQDd3IN88US=>	MnXBV2FPT0WU
MOLT-13	NHvoZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfV[o9KSzVyPUGuNFE1OjFizszN	M1rkOnNCVkeHUh?=
TE-11	MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXrJR\|UxRTFwMES4NVIh\|ryP	MYPTRW5ITVJ?
DB	NXv4cZg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGGwcZpKSzVyPUGuNFczPzNizszN	MoDvV2FPT0WU
CAL-39	NXvFVWNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLFdnFYUUN3ME2xMlA4PTJ{IN88US=>	NYTaTnFwW0GQR1XS
A3-KAW	NEPYfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\KS2lEPTB;MT6wPFQxQCEQvF2=	M4\rd3NCVkeHUh?=
CHP-134	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFi4UFVKSzVyPUGuNVE5ODdizszN	MlLkV2FPT0WU
TGW	NYq4[WM2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXPemxKSzVyPUGuNVI{QTVizszN	NEjFUW9USU6JRWK=
QIMR-WIL	M{fyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfyV2ZKSzVyPUGuNVMyOzRizszN	MnrDV2FPT0WU
NCI-SNU-1	Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIjHbHZKSzVyPUGuNVY{PTRizszN	MYPTRW5ITVJ?
CGTH-W-1	NHfiZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWn6S49JUUN3ME2xMlE4OTh4IN88US=>	MonIV2FPT0WU
MHH-ES-1	M2rtNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mk\YTWM2OD1zLkG3PVg3KM7:TR?=	M1rLOXNCVkeHUh?=
LB2241-RCC	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnDNI1KSzVyPUGuNVg3OiEQvF2=	MmflV2FPT0WU
ML-2	MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGn5fpNKSzVyPUGuNlA4OzRizszN	MnXVV2FPT0WU
COR-L23	NGLReIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPEW5pKSzVyPUGuNlI6OzNizszN	MX;TRW5ITVJ?
BFTC-905	NE\Z[mFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M37GO2lEPTB;MT6yOFI3PyEQvF2=	NUO4fZZIW0GQR1XS
Hs-578-T	NHny[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTFwMkW4NVch\|ryP	MkXxV2FPT0WU
KG-1	M1LnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFThcnFKSzVyPUGuNlY3QDZizszN	M1vBS3NCVkeHUh?=
HEL	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rOOGlEPTB;MT6yPVM{QCEQvF2=	NXT0OXhHW0GQR1XS
A549	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTFwMkmzPVkh\|ryP	M4HjXXNCVkeHUh?=
COLO-741	M4fwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPDN2hKSzVyPUGuN\|IxQDlizszN	MYXTRW5ITVJ?
PC-3	NYC2ZVZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoK3TWM2OD1zLkO1NlIyKM7:TR?=	MoDtV2FPT0WU
HOS	NUTRUlh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnlTWM2OD1zLkO1Nlk3KM7:TR?=	NGTZS4dUSU6JRWK=
HT-1080	NXnX[YVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjLTWM2OD1zLkO3OVE6KM7:TR?=	MnPOV2FPT0WU
TE-8	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTFwNEG3O\|Qh\|ryP	NYjxfZFbW0GQR1XS
BHY	M3HKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTFwNE[5NlMh\|ryP	NIfoSWhUSU6JRWK=
BB65-RCC	NV:4d4RET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorCTWM2OD1zLkWwOVI5KM7:TR?=	M{XxR3NCVkeHUh?=
HN	NWrmNZFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTFwNUSwO\|Eh\|ryP	MlfqV2FPT0WU
NCI-H441	NX3DRYdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlToTWM2OD1zLkW0PVA4KM7:TR?=	MlnWV2FPT0WU
RPMI-8866	Moe2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVf4XW1SUUN3ME2xMlU5PTB5IN88US=>	MXTTRW5ITVJ?
CAL-62	MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mny0TWM2OD1zLk[wPFYzKM7:TR?=	MnniV2FPT0WU
MG-63	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPZN2UzUUN3ME2xMlYyQDF\|IN88US=>	MojZV2FPT0WU
SK-LU-1	M4TINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlqyTWM2OD1zLk[yNVUzKM7:TR?=	MojEV2FPT0WU
BCPAP	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrYUIRxUUN3ME2xMlY3PDV5IN88US=>	MlPuV2FPT0WU
22RV1	NGDtdotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzlTWM2OD1zLk[3PFQ{KM7:TR?=	NIrPVotUSU6JRWK=
T47D	Mn63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\LV2lEPTB;MT62PFA3OSEQvF2=	MXPTRW5ITVJ?
MSTO-211H	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3ToNWlEPTB;MT62PVYxOyEQvF2=	MYfTRW5ITVJ?
DEL	Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3WXIJKSzVyPUGuO\|AzPzNizszN	NHrNVmhUSU6JRWK=
H4	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHpTWM2OD1zLkezNlEzKM7:TR?=	MU\TRW5ITVJ?
CAL-51	MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn60TWM2OD1zLke0PFU2KM7:TR?=	NUPaN3BxW0GQR1XS
ABC-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\URW9TUUN3ME2xMlc5PTh{IN88US=>	M{DVVHNCVkeHUh?=
MZ2-MEL	NUfBWWprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTFwN{m1OFIh\|ryP	MmPOV2FPT0WU
YKG-1	M3TCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTFwOEGwOlEh\|ryP	MmLjV2FPT0WU
KM12	NIL3XpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXndXlFUUN3ME2xMlgyPjB{IN88US=>	NWDaZlB[W0GQR1XS
L-363	NY\sPJpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXXOfYdCUUN3ME2xMlg4PDF{IN88US=>	NGf4SoFUSU6JRWK=
KU812	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlf5TWM2OD1zLki5NlgzKM7:TR?=	NWnvbYNIW0GQR1XS
LOXIMVI	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTFwOUGyNlgh\|ryP	MUfTRW5ITVJ?
G-401	NEfBWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3YTWM2OD1zLkmyOFI5KM7:TR?=	MlzEV2FPT0WU
SW780	M1G5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnS2TWM2OD1zLkm2NlQ3KM7:TR?=	NUDzWVlJW0GQR1XS
SW872	MoSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPCVpZoUUN3ME2xMlk5OzNizszN	MVPTRW5ITVJ?
NB7	NIfuWVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1jPSGlEPTB;MT65PVMzOyEQvF2=	MVTTRW5ITVJ?
T98G	NFHCOGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{W4Z2lEPTB;Mj6wNFY3PiEQvF2=	M2O2NXNCVkeHUh?=
SW1710	MnXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTJwME[5OFUh\|ryP	NEK5RXVUSU6JRWK=
NCI-H1573	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTDTWM2OD1{LkC3Nlk5KM7:TR?=	NEDOb2tUSU6JRWK=
KE-37	NFvtZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVKwNGt[UUN3ME2yMlA5QTVzIN88US=>	M1HGd3NCVkeHUh?=
786-0	NF7MfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTJwMUW0N\|kh\|ryP	NFSxfXlUSU6JRWK=
SAS	NV23Z4JNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTJwMkCzO\|Qh\|ryP	NIS5PYZUSU6JRWK=
CAL-54	NFnuN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILzW3hKSzVyPUKuNlA1OTNizszN	NHrVZlhUSU6JRWK=
SF268	NFHnOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfRTWM2OD1{LkKzNVIzKM7:TR?=	MYfTRW5ITVJ?
SW620	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnyVYRKSzVyPUKuNlYyPjlizszN	Ml\6V2FPT0WU
MN-60	NUjlRlZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLsTWM2OD1{LkOxNFYh\|ryP	NFm1ZmFUSU6JRWK=
EFO-27	M2TZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{TIU2lEPTB;Mj6zNlA2QCEQvF2=	MoPzV2FPT0WU
NCI-H747	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTJwM{KxPVkh\|ryP	NYjEPFFZW0GQR1XS
HCC2218	M3iyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTJwM{WzO\|Qh\|ryP	MVvTRW5ITVJ?
MIA-PaCa-2	MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DDO2lEPTB;Mj6zOlQ{PyEQvF2=	MYrTRW5ITVJ?
SJSA-1	NInuWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7HfXlKSzVyPUKuN\|c4QTZizszN	Mmr4V2FPT0WU
RKO	NGr1S25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnUS3VMUUN3ME2yMlM5PDl4IN88US=>	MX3TRW5ITVJ?
NB6	NVTJTXZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjZUm9KSzVyPUKuOFA{PzRizszN	MUHTRW5ITVJ?
ES4	MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTJwNEW0NlIh\|ryP	Mlj1V2FPT0WU
EGI-1	MmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIf0[JNKSzVyPUKuOFY5QDNizszN	MoH6V2FPT0WU
CTV-1	MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTJwNUK3O\|Mh\|ryP	NH3VPWVUSU6JRWK=
NCI-H1355	MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTJwNUW5OVEh\|ryP	M2i0NHNCVkeHUh?=
GT3TKB	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\1eHZKSzVyPUKuOVkyQTlizszN	MVzTRW5ITVJ?
SK-HEP-1	M3ruemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPtTWM2OD1{LkW5NlY3KM7:TR?=	MkTwV2FPT0WU
GAMG	NH\r[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfFd4I1UUN3ME2yMlU6Ozl2IN88US=>	NWD2eYxQW0GQR1XS
SK-MES-1	NETSe3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTJwNkG4NFMh\|ryP	M2fZ[nNCVkeHUh?=
RO82-W-1	NWfyR2pOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTzTWM2OD1{Lk[yNFU4KM7:TR?=	MUPTRW5ITVJ?
ECC10	M1m5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI[1d3FKSzVyPUKuO\|AzODZizszN	M1LwfHNCVkeHUh?=
MCF7	M2nINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYW2U3lJUUN3ME2yMlcyPDZ2IN88US=>	M{ezSXNCVkeHUh?=
D-283MED	NIfFboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjYSWpKSzVyPUKuO\|I1OyEQvF2=	MoH4V2FPT0WU
RPMI-7951	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnW0TWM2OD1{Lke1Olk1KM7:TR?=	M4Hhd3NCVkeHUh?=
Ramos-2G6-4C10	MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVK1XG15UUN3ME2yMlc4ODl7IN88US=>	NELISWVUSU6JRWK=
KGN	M1XZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nGTWlEPTB;Mj64NVg5PCEQvF2=	NX\vSXd{W0GQR1XS
NUGC-3	NEjKVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYCzflJZUUN3ME2yMlgzPTB3IN88US=>	NH2zd2NUSU6JRWK=
NCI-H292	NGHZdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTJwOEWwOVMh\|ryP	NEnYOoRUSU6JRWK=
Becker	M3;uW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHHtSmNKSzVyPUKuPVU5OzJizszN	NYDEeJFMW0GQR1XS
NCI-H1299	NIfYPZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfieXMzUUN3ME2zMlA2OjZ\|IN88US=>	MlHUV2FPT0WU
ETK-1	M4Ozcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTNwMEW0N{DPxE1?	M2D0dnNCVkeHUh?=
TK10	NGfSR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M36yV2lEPTB;Mz6yNFE3PSEQvF2=	NUDIdo1qW0GQR1XS
VMRC-RCZ	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\OSVhHUUN3ME2zMlM3PDh6IN88US=>	MlrIV2FPT0WU
YH-13	NHTpSpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTNwNESwO\|kh\|ryP	Mnv1V2FPT0WU
DU-145	NW\QSmpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFva[4JKSzVyPUOuOFYzPjlizszN	NHrDOZRUSU6JRWK=
SW1088	MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTZNWxTUUN3ME2zMlQ4PDdizszN	MorJV2FPT0WU
HOP-92	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDMZXhtUUN3ME2zMlUxOzR{IN88US=>	NWLROI5NW0GQR1XS
KP-N-YS	NHHBVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTNwNkKxN\|kh\|ryP	MYfTRW5ITVJ?
NCI-H460	MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTNwNk[3N{DPxE1?	M{fldnNCVkeHUh?=
U-2-OS	M1TvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLUSVNKSzVyPUOuO\|I2OzVizszN	NWjYcVJDW0GQR1XS
A101D	MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1S2bWlEPTB;Mz63Olk{PiEQvF2=	NVrmUmYzW0GQR1XS
MDA-MB-231	MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{P2R2lEPTB;Mz64NVk2OSEQvF2=	NFj3NI9USU6JRWK=
IST-MES1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn3HTWM2OD1\|LkizNkDPxE1?	NVLzdYg3W0GQR1XS
COR-L105	NHTmbWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTRwMEG4JO69VQ>?	M2XK[nNCVkeHUh?=
NCI-H1437	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTLPJhKSzVyPUSuNFI{ODJizszN	M4rTN3NCVkeHUh?=
CAL-85-1	M{PYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7NVFdJUUN3ME20MlAzPDZzIN88US=>	M3rXWXNCVkeHUh?=
MZ1-PC	NVvLZo8xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzwOXhKSzVyPUSuNVg2PTZizszN	MoXwV2FPT0WU
VM-CUB-1	NGfDNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlL2TWM2OD12LkOxNlg1KM7:TR?=	MnTOV2FPT0WU
CHL-1	NGnEb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoLuTWM2OD12LkOyNVY6KM7:TR?=	NGf2NlhUSU6JRWK=
MDA-MB-361	M3HYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33PTWlEPTB;ND6zN\|E2OyEQvF2=	MWPTRW5ITVJ?
NCI-H661	MorqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrPTWM2OD12LkWwNFkzKM7:TR?=	Ml7jV2FPT0WU
EW-11	NH\pc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIr4doJKSzVyPUSuOVIzOzFizszN	NYe4XWZJW0GQR1XS
BEN	M3;2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG[2[WRKSzVyPUSuOVI5OTVizszN	MVTTRW5ITVJ?
BFTC-909	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDhUFlKSzVyPUSuOVYzPzVizszN	MVTTRW5ITVJ?
NCI-H2087	Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\WTWM2OD12LkW4NVY1KM7:TR?=	MVzTRW5ITVJ?
RVH-421	M3P4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnjlTWM2OD12Lk[2Olkh\|ryP	NFj5cHBUSU6JRWK=
P30-OHK	M1Kyc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NG\JeWhKSzVyPUSuOlgxODhizszN	MmjyV2FPT0WU
NCI-H28	NV6zNYd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfjTWM2OD12LkixOlYyKM7:TR?=	MV;TRW5ITVJ?
ES6	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DO[GlEPTB;ND64N\|AyPiEQvF2=	MUDTRW5ITVJ?
769-P	NFHyfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfqUoZ6UUN3ME20Mlg2QTJ4IN88US=>	M4O3SHNCVkeHUh?=
OE33	Mo[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LReWlEPTB;ND64PFE3OSEQvF2=	NYWycWpHW0GQR1XS
SW982	MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFn3V45KSzVyPUSuPVUxPjFizszN	MmjLV2FPT0WU
A388	Mke2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfHO4l6UUN3ME21MlAzQTh\|IN88US=>	M1y5OXNCVkeHUh?=
TI-73	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LBbGlEPTB;NT6wOlE6PCEQvF2=	NHfYVYJUSU6JRWK=
HCT-116	NHvWVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHwenA4UUN3ME21MlA6QDh7IN88US=>	NEHXclJUSU6JRWK=
HuP-T3	MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTVwMUi3NFkh\|ryP	MorFV2FPT0WU
G-402	NH\pWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrLWVI3UUN3ME21MlE6PDF4IN88US=>	NHflc4lUSU6JRWK=
NCI-H1792	NULVb3JvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjsfJNKSzVyPUWuNlQ3OjJizszN	NVvBS4J1W0GQR1XS
NCI-H209	MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTVwMkW5OFIh\|ryP	MVvTRW5ITVJ?
NCI-H1650	M{PkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DmTWlEPTB;NT6zNFY{PCEQvF2=	M1XPZnNCVkeHUh?=
LCLC-97TM1	MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTVwM{G4NFgh\|ryP	M2KydnNCVkeHUh?=
S-117	NED2R4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{Dxb2lEPTB;NT6zOlk4PiEQvF2=	MkfDV2FPT0WU
GI-ME-N	NV;0U4RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGOzbm9KSzVyPUWuN\|k3QDFizszN	NX[4OIFQW0GQR1XS
NCI-H2122	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkL3TWM2OD13LkS5N\|k4KM7:TR?=	MkDkV2FPT0WU
NCI-H1793	M17JN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjCXnFKSzVyPUWuOlc2QTNizszN	NVHuWnl7W0GQR1XS
C2BBe1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TiZWlEPTB;NT63NFA5QCEQvF2=	NUO2XZBpW0GQR1XS
TE-12	NX;qXm17T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfPNHlKSzVyPUWuPFA2PTZizszN	M3XJcXNCVkeHUh?=
LCLC-103H	Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTVwOUG3JO69VQ>?	NYfi[\|EyW0GQR1XS
A673	NHG2OmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnzTWM2OD13LkmxPVMzKM7:TR?=	M3OyRnNCVkeHUh?=
BB30-HNC	M{Hkd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTVwOUizOkDPxE1?	M1TveHNCVkeHUh?=
SF295	Ml\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV3EPJBpUUN3ME22MlAxPDJ{IN88US=>	MniyV2FPT0WU
KU-19-19	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIThNmFKSzVyPU[uNFE4OzFizszN	MUTTRW5ITVJ?
CFPAC-1	M{TreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TOOWlEPTB;Nj6wOFQ1OyEQvF2=	NVjm[\|hJW0GQR1XS
LoVo	NVXT[JdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVv1[3g6UUN3ME22MlA2ODZ\|IN88US=>	M4XuR3NCVkeHUh?=
8505C	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnDTWM2OD14LkC3OVc{KM7:TR?=	MojOV2FPT0WU
GMS-10	NYrGNZZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jyfWlEPTB;Nj6xOVAxOiEQvF2=	M4fyNnNCVkeHUh?=
Ca9-22	M1S5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLRTWM2OD14LkG2O\|Eh\|ryP	NGXBcotUSU6JRWK=
DOK	NHjo[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnzXTWM2OD14LkKyNFczKM7:TR?=	M3fZZ3NCVkeHUh?=
FADU	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PGeGlEPTB;Nj6yOlA{QSEQvF2=	NUHlT41KW0GQR1XS
BxPC-3	NFj6PWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4q0VGlEPTB;Nj6yO\|MzKM7:TR?=	M3LHTXNCVkeHUh?=
CAL-33	M4LnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;jUY1KSzVyPU[uNlkzODFizszN	Mm\HV2FPT0WU
SHP-77	MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEm3U4lKSzVyPU[uN\|E2OTJizszN	MnvHV2FPT0WU
LXF-289	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\4WFA4UUN3ME22MlM{PDV3IN88US=>	MYTTRW5ITVJ?
GB-1	NWjNeIVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnnTWM2OD14LkO4NkDPxE1?	NVTTRmZMW0GQR1XS
KS-1	M2\UVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlqwTWM2OD14LkO4OFQ4KM7:TR?=	NILMfnFUSU6JRWK=
D-502MG	M{HiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF31bmRKSzVyPU[uOFI{PzZizszN	NYT2PWtzW0GQR1XS
LAN-6	NIDk[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXHTWM2OD14LkWxNFI{KM7:TR?=	Mm\aV2FPT0WU
H-EMC-SS	NFSyfWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTZwNU[xOFch\|ryP	MoHyV2FPT0WU
LC-2-ad	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TE[WlEPTB;Nj62NFA4PiEQvF2=	NHXGcFRUSU6JRWK=
NCI-H1693	MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HJRWlEPTB;Nj62NlIyPSEQvF2=	M4jKXXNCVkeHUh?=
SK-N-FI	M1zCfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zHbmlEPTB;Nj63OVA1PCEQvF2=	NGC0NFlUSU6JRWK=
D-423MG	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVL0b5IzUUN3ME22Mlc3OTF5IN88US=>	NUj1U5NxW0GQR1XS
KNS-42	MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3O1XWlEPTB;Nj63PFE6PyEQvF2=	MUPTRW5ITVJ?
GCT	NEPBNWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrWXY9KSzVyPU[uPVM5KM7:TR?=	MWHTRW5ITVJ?
DSH1	NFqycXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTdwME[zN{DPxE1?	MVXTRW5ITVJ?
D-247MG	NHjNe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2X6TGlEPTB;Nz6wO\|g5OSEQvF2=	MXLTRW5ITVJ?
NCI-SNU-5	NUTCN\|JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfMR3BOUUN3ME23MlE5OzdzIN88US=>	NX3lfopxW0GQR1XS
TE-6	M4q0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmC1TWM2OD15LkKwOlAyKM7:TR?=	NVnGW5dWW0GQR1XS
NOMO-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1W5VGlEPTB;Nz6yNlEzPyEQvF2=	MXvTRW5ITVJ?
NB17	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTdwM{CzNFkh\|ryP	MVTTRW5ITVJ?
EW-22	NEnRPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkXkTWM2OD15LkO0N\|Q5KM7:TR?=	NGrRdmNUSU6JRWK=
EW-13	NHzYSm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NETtXlhKSzVyPUeuN\|UyPjJizszN	Mm\SV2FPT0WU
DOHH-2	NGTHS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPCdVhKSzVyPUeuOFQxOiEQvF2=	NHHZe4tUSU6JRWK=
TGBC1TKB	NEH5XotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1ThbGlEPTB;Nz60PVg6QSEQvF2=	NIPRZnhUSU6JRWK=
GR-ST	NEH6V3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTdwNUK1PVQh\|ryP	NFKycG9USU6JRWK=
KYSE-520	NU\xc\|FrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTdwNUW1NVUh\|ryP	M3HwbXNCVkeHUh?=
CAPAN-1	NF3xdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{DXTmlEPTB;Nz61PVUyKM7:TR?=	MU\TRW5ITVJ?
HCE-4	M3jKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTdwNkKyO\|kh\|ryP	NX;ySGROW0GQR1XS
MLMA	NVXlN4JYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH3aeGhKSzVyPUeuOlI6PTdizszN	MYfTRW5ITVJ?
HT-144	NXrDOGNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVOxNIFkUUN3ME23MlY2OzZ6IN88US=>	NXfSOlFXW0GQR1XS
KYSE-180	NGfwZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTIToJKSzVyPUeuO\|EyPjlizszN	MVnTRW5ITVJ?
TE-5	MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDP[FZKSzVyPUeuPVU6PzFizszN	M1P4bnNCVkeHUh?=
IGROV-1	NFTubmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTdwOUi1OVEh\|ryP	NEK0bVJUSU6JRWK=
NCI-H1581	MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TKXmlEPTB;OD6wNVIh\|ryP	MXjTRW5ITVJ?
SW1990	NXTteJhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fMUGlEPTB;OD6wOFY2QSEQvF2=	MX;TRW5ITVJ?
EFM-19	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTZTWM2OD16LkC4OVQ2KM7:TR?=	NWm1fph7W0GQR1XS
OGR-1	NIDRWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfaW3ZRUUN3ME24MlQ{ODJ\|IN88US=>	MXHTRW5ITVJ?
U-118-MG	NXThcWVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TPTWlEPTB;OD60N\|Q3OyEQvF2=	M1rNN3NCVkeHUh?=
SK-OV-3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHPTWM2OD16LkS2O\|Y2KM7:TR?=	MXzTRW5ITVJ?
KNS-62	MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPTTWM2OD16LkWxO\|YyKM7:TR?=	MkTiV2FPT0WU
GOTO	M4TQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nSNWlEPTB;OD61O\|Y{PSEQvF2=	MXXTRW5ITVJ?
8305C	NEKzTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoH3TWM2OD16LkewOFg1KM7:TR?=	MXrTRW5ITVJ?
RPMI-2650	M33OVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV36UWk3UUN3ME24MlcyQTV3IN88US=>	NYfHXYJWW0GQR1XS
NEC8	M3XJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPBRWNKSzVyPUiuO\|Q{ODdizszN	MYHTRW5ITVJ?
KYSE-450	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRThwOE[1OFgh\|ryP	M{HoXHNCVkeHUh?=
RMG-I	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MU\JR\|UxRTlwMUSwOVgh\|ryP	M3[0U3NCVkeHUh?=
CAKI-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEDsUZVKSzVyPUmuN\|E6PzlizszN	MUjTRW5ITVJ?
KYSE-510	M1fLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HRbmlEPTB;OT6zOVc4QCEQvF2=	NH;RfHVUSU6JRWK=
A4-Fuk	NHLZV5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTnTWM2OD17LkO2O\|AyKM7:TR?=	M3TOWnNCVkeHUh?=
AN3-CA	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4i3UGlEPTB;OT60OVQ1PCEQvF2=	MWjTRW5ITVJ?
SK-N-DZ	NFfMPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTlwN{K4OFkh\|ryP	MUnTRW5ITVJ?
HSC-2	M3;YWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\RR5JKSzVyPUmuO\|Y3OjlizszN	NHLuclBUSU6JRWK=
EW-1	NIfrSFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjUcINKSzVyPUmuO\|k{PjlizszN	NVSxU3dkW0GQR1XS
D-566MG	NGXjdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3HTWM2OD17LkizOlY1KM7:TR?=	NEDlcXNUSU6JRWK=
COLO-792	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXv0fpo2UUN3ME25Mlk5PzR4IN88US=>	Mln6V2FPT0WU
TE-10	M3vLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vSfWlEPTB;MUCuNFM6PiEQvF2=	M1PmXnNCVkeHUh?=
NCI-H650	NWjBdVJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn;aTWM2OD1zMD60Nlg3KM7:TR?=	NYnDOHpjW0GQR1XS
U-266	NFO5TGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULHWm5NUUN3ME2xNE41PTVizszN	MV;TRW5ITVJ?
Detroit562	M2rSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHrmWphKSzVyPUGxMlA2OTVizszN	NWTDWWptW0GQR1XS
NH-12	MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\3Z2lEPTB;MUGuNVQ1PiEQvF2=	MmjhV2FPT0WU
CO-314	M4DRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrHW29lUUN3ME2xNU4zQDR{IN88US=>	MlzwV2FPT0WU
IST-MEL1	NX\Gb2pkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTFzLkWzNlMh\|ryP	Mm\5V2FPT0WU
KNS-81-FD	NFfG[I9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfx[oxKSzVyPUGxMlU2OjdizszN	MV;TRW5ITVJ?
SW1463	MorXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHv2dY9KSzVyPUGxMlU6QDlizszN	NWnKUHFxW0GQR1XS
NCI-H23	NYPESnpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjvdlY1UUN3ME2xNU43PTV{IN88US=>	M3vl[XNCVkeHUh?=
SK-MEL-2	M2jINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3foN2lEPTB;MUGuO\|E6PyEQvF2=	MUnTRW5ITVJ?
NB13	NFvocnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjQWXZ{UUN3ME2xNk4yPDl3IN88US=>	NUGwW3RxW0GQR1XS
Daoy	NILidJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWO2ZndOUUN3ME2xNk4zQDV4IN88US=>	MlPCV2FPT0WU
NCI-H1623	MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTpb5hkUUN3ME2xNk4{QDBzIN88US=>	NVL0UGRwW0GQR1XS
NMC-G1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknzTWM2OD1zMj63NVch\|ryP	NYOwfZoyW0GQR1XS
DK-MG	MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrTS4JoUUN3ME2xNk46PDh{IN88US=>	M{HWOnNCVkeHUh?=
TCCSUP	M1;rUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTF\|LkGyPFQh\|ryP	MV3TRW5ITVJ?
SCC-15	NGG5O2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DkdmlEPTB;MUOuNlY2OSEQvF2=	M4C5THNCVkeHUh?=
NOS-1	NInkSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fpbGlEPTB;MUOuNlg6OyEQvF2=	MkDKV2FPT0WU
RH-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4G0TGlEPTB;MUOuN\|A{PyEQvF2=	MnmxV2FPT0WU
SK-MEL-3	MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TKZ2lEPTB;MUOuN\|czQCEQvF2=	NYDIcHhtW0GQR1XS
NB5	NWDQSI95T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGe2SY9KSzVyPUGzMlQxPjdizszN	NIraNIFUSU6JRWK=
SNU-387	NVvZUGF{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojpTWM2OD1zMz61NFczKM7:TR?=	MmTpV2FPT0WU
CAL-120	NYPXWHNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrPU\|RpUUN3ME2xN{43PzF6IN88US=>	NWTnOZRGW0GQR1XS
Mo-T	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrtZVRKSzVyPUGzMlcxPyEQvF2=	NFPz[mVUSU6JRWK=
LNCaP-Clone-FGC	M3uyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHMTWM2OD1zMz63PVkzKM7:TR?=	NIe0UIVUSU6JRWK=
CAN	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTF2LkCyPFgh\|ryP	MlP0V2FPT0WU
SK-MEL-30	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTF2LkC2N{DPxE1?	MV;TRW5ITVJ?
COLO-678	MnWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\VOlVKSzVyPUG0MlA5OjJizszN	M2PFPXNCVkeHUh?=
SCC-9	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTF2LkGwNlEh\|ryP	NUm4UGJNW0GQR1XS
KINGS-1	NF3Nc2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;CNmlEPTB;MUSuNVQxOiEQvF2=	MXvTRW5ITVJ?
SL-513	M4DkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTF2LkG4O{DPxE1?	MXjTRW5ITVJ?
HLE	NWTBWWFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTF2LkO4OVIh\|ryP	M{LjO3NCVkeHUh?=
SW1573	NUH3dlRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjyWFNKSzVyPUG0MlQ1OzVizszN	NHPGNGVUSU6JRWK=
KYSE-140	M{\TcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3ntVWlEPTB;MUSuOlMzPyEQvF2=	MoX0V2FPT0WU
SK-PN-DW	M2Xzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljJTWM2OD1zND64NFAyKM7:TR?=	MkXvV2FPT0WU
A253	MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;oTWM2OD1zNT6wOlI2KM7:TR?=	MXfTRW5ITVJ?
CAL-12T	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTF3LkS2OlIh\|ryP	NH\WZpFUSU6JRWK=
COLO-679	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHJR\|UxRTF3Lke2PFMh\|ryP	NH3aN4tUSU6JRWK=
UACC-257	NYrUd4RUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoX3TWM2OD1zNj6xNlAyKM7:TR?=	MkjsV2FPT0WU
U-87-MG	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PJNmlEPTB;MU[uN\|UzOyEQvF2=	M4LO[3NCVkeHUh?=
HCC1806	NXXIemFST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXr4e\|BkUUN3ME2xOk44ODdzIN88US=>	NVvGZ2VZW0GQR1XS
NCI-H2170	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TH[WlEPTB;MUeuNlQ1QCEQvF2=	M3HSSHNCVkeHUh?=
AGS	M{\RRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvNSmJKSzVyPUG3MlM5ODhizszN	MX\TRW5ITVJ?
MEL-HO	NGHrXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHToOG5KSzVyPUG3Mlc2ODNizszN	M37tS3NCVkeHUh?=
SW48	NXzvUG5TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlL5TWM2OD1zNz63O\|E3KM7:TR?=	Ml3YV2FPT0WU
HuP-T4	MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTF6LkCyNFYh\|ryP	NH7zWJNUSU6JRWK=
NCI-H720	M2TRfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPxTWM2OD1zOD6xOFAzKM7:TR?=	MV\TRW5ITVJ?
RCC10RGB	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYi2SY5FUUN3ME2xPE4yPjl5IN88US=>	MkHaV2FPT0WU
HD-MY-Z	Mn7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPQTWM2OD1zOD6yNlU1KM7:TR?=	M4f6[HNCVkeHUh?=
A427	MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTF6LkWwPVQh\|ryP	NWq2UpdKW0GQR1XS
HCC2998	M{i5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkizTWM2OD1zOD62NFUyKM7:TR?=	MnjjV2FPT0WU
EPLC-272H	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXPfXIxUUN3ME2xPU4xPDN2IN88US=>	NYXKdXpKW0GQR1XS
C32	M4PF[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTF7LkC0OUDPxE1?	M{PqfXNCVkeHUh?=
UMC-11	MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzldppoUUN3ME2xPU4zOTJ\|IN88US=>	Moj5V2FPT0WU
CaR-1	M4fDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHNXWoxUUN3ME2xPU43QDB2IN88US=>	Mk\2V2FPT0WU
KYSE-410	MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnB[IVuUUN3ME2xPU46OTN7IN88US=>	MojOV2FPT0WU
HuCCT1	NYjReWlzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTJyLk[yPVQh\|ryP	MXHTRW5ITVJ?
LB996-RCC	Mny0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDLTWM2OD1{MD63NVY5KM7:TR?=	MXjTRW5ITVJ?
KYSE-70	M{jjVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVGydWhMUUN3ME2yNE45ODV7IN88US=>	M163WHNCVkeHUh?=
CAL-72	M13VV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWSx[IJvUUN3ME2yNE46OTVizszN	MkP1V2FPT0WU
Capan-2	MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7FTWM2OD1{MT6wOFE{KM7:TR?=	MYjTRW5ITVJ?
PANC-08-13	M1y5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGey[lBKSzVyPUKxMlI2OTVizszN	NUDreVlpW0GQR1XS
SBC-1	NHH3Z4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XBU2lEPTB;MkGuN\|A5OSEQvF2=	M1HtXXNCVkeHUh?=
MFM-223	NUK1[YhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnmVnZSUUN3ME2yNU4{OzR{IN88US=>	MnXwV2FPT0WU
BB49-HNC	NFTsd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTJzLkW3NVYh\|ryP	MmTTV2FPT0WU
SH-4	NXLNSGc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTJzLk[2NVgh\|ryP	NHvaWGxUSU6JRWK=
HuO9	Moj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mof1TWM2OD1{MT65PFI2KM7:TR?=	MV;TRW5ITVJ?
AM-38	MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXX0cnNrUUN3ME2yNk4xPDh3IN88US=>	NIrWWFdUSU6JRWK=
A431	NFXRXoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXfUV41rUUN3ME2yN{4zOTF7IN88US=>	MX;TRW5ITVJ?
YAPC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nkZ2lEPTB;MkOuNlY2OSEQvF2=	MWrTRW5ITVJ?
LU-139	NXPuSGR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{mwXWlEPTB;MkOuOFgxQSEQvF2=	NFTxeJFUSU6JRWK=
HEC-1	M4S0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTJ\|LkS5N\|ch\|ryP	M3f4N3NCVkeHUh?=
SCC-25	MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfCNFJrUUN3ME2yOE4{ODB4IN88US=>	MlHNV2FPT0WU
HT-29	NFHYcWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjwTWM2OD1{ND6zPFI{KM7:TR?=	NIDsXIhUSU6JRWK=
PC-14	NV3vUVNXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWCxTINzUUN3ME2yOE43PTdzIN88US=>	MlHjV2FPT0WU
Calu-6	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTDTWM2OD1{NT61NFcyKM7:TR?=	NUTSRnFmW0GQR1XS
SJRH30	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGexS4pKSzVyPUK1MlY1QTZizszN	MoexV2FPT0WU
ChaGo-K-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTiZoFSUUN3ME2yOk4yPjJ7IN88US=>	NIrZSGZUSU6JRWK=
IA-LM	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF21bmtKSzVyPUK2MlM3PDVizszN	MlXlV2FPT0WU
GP5d	NGHjZ3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnjTZFUUUN3ME2yOk41PDlzIN88US=>	NHnkV4NUSU6JRWK=
NCI-H2291	NIfSXGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTJ4Lk[1OFEh\|ryP	NXWyeGtWW0GQR1XS
BALL-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTsTWM2OD1{Nj65N\|k4KM7:TR?=	NFWxSZhUSU6JRWK=
HCC1954	M4f1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlnKTWM2OD1{Nj65PFA5KM7:TR?=	MoPEV2FPT0WU
NCI-H2452	MkPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPCTWM2OD1{Nz60NVY{KM7:TR?=	MoTTV2FPT0WU
LU-99A	NIT0RpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3f2emlEPTB;MkeuOVU5OiEQvF2=	MWjTRW5ITVJ?
NTERA-S-cl-D1	MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;IT\|JYUUN3ME2yO{44Ojl7IN88US=>	M3[zOXNCVkeHUh?=
PANC-10-05	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXHS4dZUUN3ME2yO{44Pzd3IN88US=>	Mlz5V2FPT0WU
NCI-H2405	Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfMVWpWUUN3ME2yO{46Ozh5IN88US=>	M1viXXNCVkeHUh?=
MDA-MB-415	NYLucIFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;MNFFKSzVyPUK4MlQyOzdizszN	NYSwO5pWW0GQR1XS
NCI-H2342	Mn3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3VTWM2OD1{OD61NlgyKM7:TR?=	NVzONWlPW0GQR1XS
TGBC24TKB	NFvSSZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnS5TWM2OD1{OD63NVE4KM7:TR?=	MUXTRW5ITVJ?
LU-134-A	Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1PLZWlEPTB;MkiuPVI3OSEQvF2=	NXXMOJJwW0GQR1XS
SCC-4	M4D4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4nCU2lEPTB;M{GuNFQ6PCEQvF2=	Mlq1V2FPT0WU
Saos-2	M33XcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PRZWlEPTB;M{GuPVMxPiEQvF2=	NHu3cIhUSU6JRWK=
RERF-LC-MS	Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PPXmlEPTB;M{KuPFI{OSEQvF2=	NHv0ZXlUSU6JRWK=
M14	Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHyWVVKSzVyPUOyMlk4PjRizszN	MWTTRW5ITVJ?
HPAF-II	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnaeolKSzVyPUOzMlUxOTFizszN	MVXTRW5ITVJ?
NCI-H1755	Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITaSYZKSzVyPUO0MlM{ODVizszN	M{fMUXNCVkeHUh?=
D-392MG	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTN3Lki2O\|Qh\|ryP	MlPFV2FPT0WU
A704	NHnRO\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\MTWM2OD1\|Nj6wOFI4KM7:TR?=	M37JSXNCVkeHUh?=
CP50-MEL-B	NGTW[mZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVvJR\|UxRTN4LkG5NVEh\|ryP	NHfXfJBUSU6JRWK=
EW-18	MonPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2r3c2lEPTB;M{[uOFUzKM7:TR?=	Mli1V2FPT0WU
WM-115	M4rNT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIDKTmpKSzVyPUO2MlgxQTlizszN	MUHTRW5ITVJ?
LU-65	NXiycJlQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2T2NWlEPTB;M{euNVQyPyEQvF2=	MnXRV2FPT0WU
NCI-H1563	MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTN5LkK0PFQh\|ryP	MmDWV2FPT0WU
DBTRG-05MG	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTN6LkC2PVEh\|ryP	NGjBepFUSU6JRWK=
NCI-H630	NX;PN5pxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\rV2pKSzVyPUO4MlQ4OTRizszN	NY\4eWNRW0GQR1XS
NCI-H1155	MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXTocHNnUUN3ME2zPU4zPDJizszN	NVWxeoZCW0GQR1XS
OVACR-3	MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHJWVVKSzVyPUO5MlkyQTVizszN	MnqyV2FPT0WU
OAW-42	MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTRyLkSyOVgh\|ryP	NWniTFZ4W0GQR1XS
JVM-2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTRzLkK0NVUh\|ryP	MULTRW5ITVJ?
C3A	MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\2TFFPUUN3ME20NU4{PDR5IN88US=>	MYLTRW5ITVJ?
HT55	NYrlNWt7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3zuSmlEPTB;NEKuNlg1OSEQvF2=	M3HNNXNCVkeHUh?=
OVCAR-4	NHjTXnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTR{LkK5O\|Qh\|ryP	MYLTRW5ITVJ?
MEG-01	NUWxSVhyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jRe2lEPTB;NEKuOFYyPiEQvF2=	M1HTSHNCVkeHUh?=
NCI-H82	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFnqeppKSzVyPUSzMlk5QTJizszN	MoXTV2FPT0WU
JEG-3	MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTR2Lkm0O{DPxE1?	MYDTRW5ITVJ?
BPH-1	MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTNTWM2OD12Nj6zPVk5KM7:TR?=	MmD5V2FPT0WU
MPP-89	M3XUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjJTWM2OD12Nz6yPFk5KM7:TR?=	NGrBWGdUSU6JRWK=
ALL-PO	NXfvNWtET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\hTWM2OD12Nz60NVg5KM7:TR?=	M3m0TXNCVkeHUh?=
HT	Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDrWGVKUUN3ME20O{41QTJizszN	MkfHV2FPT0WU
NCI-H2347	M{X2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnnXTWM2OD12OD6wO\|E2KM7:TR?=	NWrFO4k4W0GQR1XS
A2780	NV7GSZlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;uOmtGUUN3ME20PU41OjJ6IN88US=>	M1uyNHNCVkeHUh?=
KARPAS-299	NFPvNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEf3NlBKSzVyPUS5MlUyOTlizszN	NYHMVpAzW0GQR1XS
NCI-H1651	MkHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHVTWM2OD12OT64PFIyKM7:TR?=	M1zEO3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; PubMed: 30300583 Cancer Cell Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells. pRb(S807, 811) / CDK4 / CDK6 / PARP; PubMed: 28453226 Mol Oncol Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. LC3-I / LC3-II; PubMed: 28453226 Mol Oncol Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. pAMPKα(T172) / pULK1(S317); PubMed: 28453226 Mol Oncol Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. SMAD2 (pS255); PubMed: 30343527 Cancer Sci T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.	30300583 28453226 30343527
Growth inhibition assay	Cell viability; PubMed: 29670090 Cell Death Dis Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.	29670090
Immunofluorescence	SAHF/ATRX; PubMed: 26988987 Cancer Res DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. LC3B; PubMed: 28453226 Mol Oncol LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).	26988987 28453226
ELISA	PGE2; PubMed: 26540629 Oncotarget The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.	26540629

In vivo

PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse Cdk Assays: A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl₂, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-³²P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-³²P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-³²P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4 °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research: ^[1]	- Collapse Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562 Concentrations: 0.01-1 μM Incubation Time: 24 hours Method: Cells are seeded at 2 × 10⁴ per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [¹⁴C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice. Dosages: 0-150 mg/kg Administration: Given by gavage (Only for Reference)

References

[4] Katsumi Y, et al. Biochem Biophys Res Commun, 2011, 413(1), 62-68.

- Collapse

Solubility (25°C)

In vitro	Water	30 mg/mL (61.98 mM)
	DMSO	3 mg/mL warmed (6.19 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Molecular Weight	483.99
Formula	C₂₄H₂₉N₇O₂.HCl
CAS No.	827022-32-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	Cl.CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N4CCNCC4)N=C2N(C5CCCC5)C1=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04360941	Not yet recruiting	Drug: Palbociclib\|Drug: Avelumab	Triple Negative Breast Cancer\|Locally Advanced Breast Cancer\|Recurrent Breast Cancer\|Metastatic Breast Cancer\|ER+ Breast Cancer\|HER2-positive Breast Cancer	Royal Marsden NHS Foundation Trust\|Pfizer\|Breast Cancer Now	July 1 2020	Phase 1
NCT03870919	Suspended	Drug: Palbociclib\|Other: locoregional treatment	Breast Cancer Stage IV\|Radiotherapy\|Surgery	UNICANCER\|Pfizer	October 23 2019	Not Applicable
NCT03900884	Not yet recruiting	Drug: Venetoclax\|Drug: Palbociclib\|Drug: Letrozole	Breast Neoplasm Female	Peter MacCallum Cancer Centre Australia	September 2019	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Most Potent CDK Inhibitor

LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.
CDK Inhibitor in Clinical Trial

Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).
Newest CDK Inhibitor

NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.
Flavopiridol HCl

Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
Roscovitine (Seliciclib,CYC202)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
abemaciclib mesylate (LY2835219)

abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.
SNS-032 (BMS-387032)

SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

Palbociclib (PD-0332991) HCl